The Full Picture of Ulcerative Colitis: the Burden, the Patient, the Treatment

Disclosure: Julián Panés has received grants/research support from Abbott Laboratories and Merck Sharp & Dohme Corp.; consulting/speaker fees from AbbVie, Abbott Laboratories, Boehringer Ingelheim, Ferring, Galapagos, Genentech, Janssen Biologics, Merck Sharp & Dohme Corp., Millennium (Takeda), MSD, Pfizer, Roche, Shire, Schering-Plough, Takeda, Tigenix, and TxCell. Edouard Louis has received educational grants from MSD and Abbvie; speaker fees from Abbvie, Ferring, MSD, Chiesi, Mitsubishi Pharma, Hospira, and Janssen; and has served on advisory boards for Abbvie, Ferring, MSD, Takeda, Mitsubishi Pharma, and Celltrion. Acknowledgements: Writing assistance was provided by Dr Allan Johnson, Medical Writing Limited. Support: The symposium was jointly organised and funded by Abbvie. All authors received honoraria for preparation and delivery of their presentations. The publication of this article was funded by Abbvie. This article is an interpretation of the views of the speakers, but is not written by them. The views and opinions expressed are those of the authors and not necessarily those of Abbvie. Citation: EMJ Gastroenterol. 2015;4(1):58-65.